SynthesisFrontiers in oncology2025
Prognostic value of platelet to lymphocyte ratio in patients with castration-resistant prostate cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune-inflammation index as prognostic markers in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Vitamin D and adverse pathologic features in patients undergoing radical prostatectomy in the contemporary magnetic resonance imaging-guided management era.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although the platelet-to-lymphocyte ratio (PLR) has been identified as a prognostic marker in various cancers, its role in castration-resistant prostate cancer (CRPC) remains uncertain. This meta-analysis examines the prognostic significance of PLR in relation to overall survival (OS) and progression-free survival (PFS) in patients with CRPC. Methods: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library up to March 11, 2025. Two reviewers independently screened studies, extracted data, and assessed quality using the Newcastle-Ottawa Scale (NOS). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Sensitivity and subgroup analyses explored heterogeneity and assessed result stability. All analyses were performed using Review Manager 5.4 and STATA 15.0. Results: A total of 13 studies (14 comparison groups; 2,405 patients) were included. High PLR was significantly associated with shorter OS (HR = 1.62, 95% CI: 1.30-2.03), but not with PFS (HR = 1.25, 95% CI: 0.92-1.69). Subgroup analyses confirmed the association with poor OS in prospective studies, patients aged ≥72, European populations, those on hormone therapy, and studies using a PLR cut-off ≥150. Heterogeneity mainly arose from differences in study design, treatment, and region. Sensitivity analyses and Egger's test confirmed the robustness of findings with no publication bias. Discussion: PLR is a significant predictor of OS in CRPC and may help guide clinical risk stratification. However, its role in predicting PFS is limited. Further prospective studies are needed to validate its clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.